Description: SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.
Home Page: senzagen.com
Building 401
Lund,
223 81
Sweden
Phone:
46 4 62 75 60 00
Officers
| Name | Title |
|---|---|
| Mr. Peter Nahlstedt | Pres & CEO |
| Ms. Marianne Olsson | VP of Fin. |
| Ms. Asa Nyhlen | VP of Operations |
| Dr. Henrik Johansson | Chief Scientist |
| Ms. Tina Dackemark Lawesson | VP of Marketing & Communications |
| Ms. Anna Chérouvrier Hansson | VP of Sales & Bus. Devel.. |
| Ms. Helen Olsson | VP of HR |
| Dr. Marisa Meloni | Founder & CEO of VitroScreen S.r.l. |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.3056 |
| Price-to-Sales TTM: | 10.6921 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |